Andreas Saltos, MD
Dr. Andreas Saltos is a board-certified medical oncologist at the Moffitt Cancer Center in Tampa, Florida. He specializes in treating patients with thoracic malignancies, including those diagnosed with malignant pleural mesothelioma and all types of lung cancer, at all stages.
His treatment approach is centered on identifying the most appropriate treatment protocol to meet his patients’ conditions and personal goals, and does so with the support of Moffitt Cancer Center’s multidisciplinary team of cancer specialists.
Education and Career
Dr. Saltos earned his medical degree at the University of Maryland Medical Center in Baltimore, Maryland, and remained there for his internship and residency in Internal Medicine. He completed a fellowship in Hematology and Medical Oncology at the University of South Florida Moffitt Cancer Center and then joined the staff at Moffitt Cancer Center as a Medical Oncologist and the Clinical Research Medical Director in the Department of Thoracic Oncology.[1]
Research
Dr. Saltos is actively involved in clinical research targeting lung cancer protocols that improve patient outcomes. He is particularly interested in the use of targeted therapies and immunotherapy
He is currently leading and developing clinical trials investigating novel drugs or treatment combinations that either target the specific genetic features of lung cancers or recruit the immune system to combat cancer.[1]
Those trials include:[1]
Clinical Trial 20178
An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Condition: Thoracic
Intervention: AZD9291 (Osimertinib); IMC-1121B (Ramucirumab); Osimertinib (); Ramucirumab ()
Status: Open
Clinical Trial 20530
Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Condition: Thoracic
Status: Open
Clinical Trial 21586
LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early-Stage Lung Cancer
Condition: Thoracic
Status: Open
Clinical Trial 21701
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: NGM438 (); NGM831 (); Pembrolizumab (Keytruda)
Status: Open
Clinical Trial 21941
A Phase 2 Study of Mecbotamab (BA3011) Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on or Are Intolerant to a PD- 1/L1, EGFR or ALK Inhibitor
Condition: Thoracic
Intervention: BA3011 (Mecbotamab Vedotin); BMS-936558 (Nivolumab); Nivolumab (Opdivo)
Status: Open
Clinical Trial 22164
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer (PALOMA-2).
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Amivantamab (); JNJ-61186372 (Amivantamab); JNJ-73841937 (Lazertinib); Lazertinib (); Paraplatin (carboplatin); Pemetrexed (); carboplatin ()
Status: Open
Clinical Trial 22484
PRAGMATICA LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Condition: Thoracic
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); IMC-1121B (Ramucirumab); Nab-paclitaxel (Abraxane); Pembrolizumab (Keytruda); Pemetrexed (); Ramucirumab (); Taxotere (docetaxel); docetaxel (); gemcitabine ()
Status: Open
Dr. Saltos’ recent publications include:[1]
- Saltos AN, Creelan BC, Tanvetyanon T, Chiappori AA, Antonia SJ, Shafique MR, Ugrenovic-Petrovic M, Sansil S, Neuger A, Ozakinci H, Boyle TA, Kim J, Haura EB, Gray JE. A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations. Lung Cancer. 2023 Sep.183:107313. Pubmedid: 37499521.
- Gilardone S, Thapa R, Laborde J, Shafique M, Saltos A, Creelan B, Tanvetyanon T, Chiappori A, Simon G, Haura EB, Gray JE, Chen DT, Melzer D, Pellini B. Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. J Thorac Dis. 2023 Nov.15(11):6115-6125. Pubmedid: 38090314. Pmcid: PMC10713299.
- Liveringhouse CL, Latifi K, Asous AG, Lam NB, Rosenberg SA, Dilling TJ, MacMillan GV, Chiappori AA, Haura EB, Creelan B, Gray JE, Tanvetyanon T, Shafique MR, Saltos AN, Weiner AA, Clarke J, Kelsey CR, Kim S, Caudell JJ, Rose TA, Conejo-Garcia JR, Li J, Schell MJ, Antonia SJ, Perez BA. Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):837-848. Pubmedid: 36657497.
- Puri S, Saltos AN, Gray JE. Race-inclusive and equitable access to immune checkpoint inhibitor therapy: What are the biggest hurdles? Cancer. 2023 Dec.129(23):3692-3693. Pubmedid: 37728029.
- Dudek AZ, Xi MX, Scilla KA, Mamdani H, Creelan BC, Saltos A, Tanvetyanon T, Chiappori A. Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299. JTO Clin Res Rep. 2023 Dec.4(12):100584. Pubmedid: 38046376. Pmcid: PMC10689266.
- Zheng H, Yu X, Ibrahim ML, Foresman D, Xie M, Johnson JO, Boyle TA, Ruffell B, Perez BA, Antonia SJ, Ready N, Saltos AN, Cantwell MJ, Beg AA. Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity. Cancer Immunol Res. 2023 Apr.11(4):466-485. Pubmedid: 36757308. Pmcid: PMC10165690.
- Chen DT, Saltos AN, Rose T, Thompson ZJ, Thapa R, Chiappori A, Gray JE. Early Adverse Event Derived Biomarkers in Predicting Clinical Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers (Basel). 2023 Apr.15(9). Pubmedid: 37173987. Pmcid: PMC10177532.
- Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022 Jan.386(3):241-251. Pubmedid: 34534430. Pmcid: PMC9066448.
- Turner K, Brownstein NC, Thompson Z, El Naqa I, Luo Y, Jim HSL, Rollison DE, Howard R, Zeng D, Rosenberg SA, Perez B, Saltos A, Oswald LB, Gonzalez BD, Islam JY, Alishahi Tabriz A, Zhang W, Dilling TJ. Longitudinal patient-reported outcomes and survival among early-stage non-small cell lung cancer patients receiving stereotactic body radiotherapy. Radiother Oncol. 2022 Feb.167:116-121. Pubmedid: 34953934. Pmcid: PMC8934278.
- Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late-stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
